切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2025, Vol. 14 ›› Issue (02) : 238 -244. doi: 10.3877/cma.j.issn.2095-3232.2025040

临床研究

同期手术治疗同时性结直肠癌肝转移的安全性与疗效
姚焕章1, 宋华传1, 王永帅1, 张珅瑜1, 王继洲1,()   
  1. 1. 230031 合肥,安徽医科大学附属省立医院肝胆外科
  • 收稿日期:2024-12-10 出版日期:2025-04-10
  • 通信作者: 王继洲
  • 基金资助:
    国家自然科学基金(82170618)

Safety and efficacy of simultaneous surgery for synchronous colorectal cancer liver metastasis

Huanzhang Yao1, Huachuan Song1, Yongshuai Wang1, Kunyu Zhang1, Jizhou Wang1,()   

  1. 1. Department of Hepatobiliary Surgery, Provincial Hospital Affiliated to Anhui Medical University, Hefei 230031, China
  • Received:2024-12-10 Published:2025-04-10
  • Corresponding author: Jizhou Wang
引用本文:

姚焕章, 宋华传, 王永帅, 张珅瑜, 王继洲. 同期手术治疗同时性结直肠癌肝转移的安全性与疗效[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 238-244.

Huanzhang Yao, Huachuan Song, Yongshuai Wang, Kunyu Zhang, Jizhou Wang. Safety and efficacy of simultaneous surgery for synchronous colorectal cancer liver metastasis[J/OL]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2025, 14(02): 238-244.

目的

探讨同期手术治疗同时性结直肠癌肝转移(SCRLM)的安全性与疗效。

方法

回顾性分析2017 年8 月至2023 年2 月在安徽医科大学附属省立医院行根治性手术治疗的100 例SCRLM 患者临床资料。患者均签署知情同意书,符合医学伦理学规定。根据手术时机不同,分为同期组(70 例)和分期组(30 例)。比较两组患者术前CEA、CA19-9 水平,原发肿瘤类型、术后病理,肝转移病灶部位、大小、数目,术中出血量、手术时间、住院时间、住院费用、术后并发症以及无复发生存等情况。两组围手术期指标比较采用Mann-Whitney U 检验,率的比较采用χ2 检验或Fisher 确切概率法。无复发生存期(RFS)分析采用Kaplan-Meier 法和Log-rank 检验,生存预后影响因素分析采用Cox比例风险回归模型。

结果

两组患者均无术后30 d 内死亡。同期组与分期组手术时间中位数分别为287(216,349)、310(267,399)min,术中出血量分别为150(100,200)、100(50,150)ml,住院时间分别为18(15,25)、28(24,32)d,住院费用分别为5.8(4.9,7.3)、8.6(7.9,9.6)万元,差异均有统计学意义(Z=-2.03,0.96,-4.94,-0.86;P<0.05);同期组与分期组输血患者分别为21、2 例,差异有统计学意义(χ2=6.46,P<0.05)。同期组、分期组术后复发分别为50、22 例,中位RFS 分别为6.0、8.5 个月,差异无统计学意义(χ2=0.46,P>0.05)。Cox 多因素回归分析显示,原发肿瘤T3~T4 期、肝脏多发病灶、KRAS 突变、CA19-9>100 kU/L 以及新辅助化疗是患者预后的独立危险因素(HR=10.88,0.57,3.66,1.28,0.66;P<0.05)。

结论

同期手术治疗SCRLM 可缩短手术和住院时间,住院费用更少,虽然增加了一定的出血量,但并未增加术后并发症发生率,具有与分期手术相当的RFS。对于SCRLM 患者行同期手术治疗安全且有效。

Objective

To investigate the safety and efficacy of simultaneous surgical resection for synchronous colorectal cancer liver metastasis (SCRLM).

Methods

Clinical data of 100 patients with SCRLM who underwent radical surgery in Provincial Hospital Affiliated to Anhui Medical University, from August 2017 to February 2023 were analyzed retrospectively.The informed consents of all patients were obtained and the local ethical committee approval was received.According to different surgical timing,all patients were divided into the simultaneous surgery group (n=70) and staged surgery group (n=30).Preoperative CEA and CA19-9 levels, primary tumor type, postoperative pathology, location, size and number of liver metastases, intraoperative blood loss, operation time, length of hospital stay, hospitalization expenses,postoperative complications and recurrence-free survival were compared between two groups.Perioperative indexes between two groups were compared by Mann-Whitney U test.The rates were compared by Chisquare test or Fisher’s exact probability test.Recurrence-free survival (RFS) was compared by Kaplan-Meier method and Log-rank test.Prognostic factors were analyzed by Cox proportional hazards regression model.

Results

No patient died within postoperative 30 d in two groups.In the simultaneous and staged surgery groups, the median operation time was 287(216,349) and 310(267, 399) min, intraoperative blood loss was 150(100, 200) and 100(50, 150) ml, the length of hospital stay was 18(15, 25) and 28(24, 32) d and hospitalization expense was 5.8×104 (4.9×104, 7.3×104) and 8.6×104 (7.9×104, 9.6×104) Yuan, respectively.The differences were statistically significant between two groups (Z=-2.03, 0.96, -4.94 and -0.86; all P<0.05).In the simultaneous surgery group, 21 patients received blood transfusion and 2 in the staged surgery group, and the difference was statistically significant (χ2=6.46, P<0.05).In the simultaneous and staged surgery groups, 50 and 22 patients experienced postoperative recurrence, and the median RFS was 6.0 and 8.5 months,with no statistical significance between two groups (χ2=0.46, P>0.05).Multivariate Cox regression analysis showed that stage T3-T4 primary tumor, multiple liver lesions, KRAS mutation, CA19-9>100 kU/L and neoadjuvant chemotherapy were the independent risk factors for clinical prognosis (HR=10.88, 0.57, 3.66, 1.28,0.66; all P<0.05).

Conclusions

Simultaneous surgery can shorten the operation time and length of hospital stay, reduce hospitalization expenses for SCRLM patients.Although it increases the amount of intraoperative bleeding, it does not elevate the incidence of postoperative complications, and yields equivalent recurrence-free survival to staged surgery.Simultaneous surgery is safe and effective for patients with SCRLM.

表1 同期组和分期组SCRLM 患者一般资料比较
表2 两组SCRLM 患者手术及术后病理等相关情况比较
表3 两组SCRLM 患者术后并发症发生情况比较(例)
表4 SCRLM 患者根治性手术后预后影响因素的Cox 回归分析
[1]
Sung H, Ferlay J, Siegel RL, et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin, 2021, 71(3): 209-249.DOI: 10.3322/caac.21660.
[2]
Siegel R, Wagle NS, Cercek A, et al.Colorectal cancer statistics,2023[J].CA A Cancer J Clin, 2023, 73: 233-254.DOI: 10.3322/caac.21772.
[3]
朱德祥, 任黎, 许剑民.中国结直肠癌肝转移诊断和综合治疗指南(2020版)[J].中国实用外科杂志, 2021, 41(1): 1-11.DOI: 10.19538/j.cjps.issn1005-2208.2021.01.01.Zhu DX, Ren L, Xu JM.China guideline for diagnosis and comprehensive treatment of colorectal liver metastases(2020 edition)[J].Chin J Pract Surg, 2021, 41(1): 1-11.DOI: 10.19538/j.cjps.issn1005-2208.2021.01.01.
[4]
段键, 何金兰, 曾仲.结直肠癌肝转移的多学科团队治疗[J].中华消化外科杂志, 2021, 20(12): 1370-1372.DOI: 10.3760/cma.j.cn 115610-20210929-00484.Duan J, He JL, Zeng Z.Multidisciplinary treatment of colorectal liver metastasis[J].Chin J Dig Surg, 2021, 20(12): 1370-1372.DOI:10.3760/cma.j.cn115610-20210929-00484.
[5]
Wisneski AD, Jin C, Huang CY, et al.Synchronous versus metachronous colorectal liver metastasis yields similar survival in modern era[J].J Surg Res, 2020, 256: 476-485.DOI: 10.1016/j.jss.2020.06.038.
[6]
Ghiasloo M, Pavlenko D, Verhaeghe M, et al.Surgical treatment of stage IV colorectal cancer with synchronous liver metastases: a systematic review and network meta-analysis[J].Eur J Surg Oncol,2020, 46(7): 1203-1213.DOI: 10.1016/j.ejso.2020.02.040.
[7]
王明帅, 王宏伟, 包全, 等.结直肠癌肝转移术后预后分析——单中心20年经验分享[J].中华转移性肿瘤杂志, 2024, 7(1): 10-17.DOI:10.3760/cma.j.cn101548-20231114-00116.Wang MS, Wang HW, Bao Q, et al.Postoperative prognostic analysis of colorectal liver metastasis: a single center 20-year experience sharing[J].Chin J Metastatic Cancer, 2024, 7(1): 10-17.DOI: 10.3760/cma.j.cn101548-20231114-00116.
[8]
罗治文, 陈晓, 张业繁, 等.同时性结直肠癌肝转移术后早期复发的影响因素[J].中华肝胆外科杂志, 2020, 26(10): 741-747.DOI:10.3760/cma.j.cn113884-20200811-00426.Luo ZW, Chen X, Zhang YF, et al.Influencing factors of early recurrence after liver metastasis of synchronous colorectal cancer[J].Chin J Hepatobiliary Surg, 2020, 26(10): 741-747.DOI: 10.3760/cma.j.cn113884-20200811-00426.
[9]
Pagani M, De Vincenti R, Cecchi C, et al.Hepatic resection in patients with colo-rectal liver metastases: surgical outcomes and prognostic factors of single-center experience[J].J Clin Med, 2023, 12(6): 2170.DOI: 10.3390/jcm12062170.
[10]
Ali SM, Pawlik TM, Rodriguez-Bigas MA, et al.Timing of surgical resection for curative colorectal cancer with liver metastasis[J].Ann Surg Oncol, 2018, 25(1): 32-37.DOI: 10.1245/s10434-016-5745-7.
[11]
Abelson JS, Michelassi F, Sun T, et al.Simultaneous resection for synchronous colorectal liver metastasis: the new standard of care?[J].J Gastrointest Surg, 2017, 21(6): 975-982.DOI: 10.1007/s11605-017-3422-1.
[12]
Machairas N, Di Martino M, Primavesi F, et al.Simultaneous resection for colorectal cancer with synchronous liver metastases: current stateof-the-art[J].J Gastrointest Surg, 2024, 28(4): 577-586.DOI: 10.1016/j.gassur.2024.01.034.
[13]
Zhou J, Feng L, Li X, et al.The value of laparoscopic simultaneous colorectal and hepatic resection for synchronous colorectal cancer liver metastasis: a propensity score matching study[J].Front Oncol,2022, 12: 916455.DOI: 10.3389/fonc.2022.916455.
[14]
翟升永, 孙晓静, 钟晓东, 等.手术治疗对于同时性结直肠癌肝转移预后的影响[J].中华普通外科杂志, 2018, 33(11): 915-919.DOI:10.3760/cma.j.issn.1007-631X.2018.11.006.Zhai SY, Sun XJ, Zhong XD, et al.Effect of surgical treatment on prognosis of simultaneous liver metastasis of colorectal cancer[J].Chin J Gen Surg, 2018, 33(11): 915-919.DOI: 10.3760/cma.j.issn.1007-631X.2018.11.006.
[15]
Chandra P, Sacks GD.Contemporary surgical management of colorectal liver metastases[J].Cancers, 2024, 16(5): 941.DOI: 10.3390/cancers16050941.
[16]
Bolton JS, Fuhrman GM.Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma[J].Ann Surg, 2000,231(5): 743-751.DOI: 10.1097/00000658-200005000-00015.
[17]
Huang L, Tang X, Fang J, et al.Synchronous colorectal liver metastases considering infectious complications: simultaneous or delayed surgery?[J].Evid Based Complement Alternat Med, 2022,2022: 5268554.DOI: 10.1155/2022/5268554.
[18]
Choong K, Wong P, Thornblade L, et al.Combined liver and colon resection of synchronous colorectal liver metastases at a quaternary center[J].J Surg Res, 2023, 288: 252-260.DOI: 10.1016/j.jss.2023.03.008.
[19]
Gavriilidis P, Sutcliffe RP, Hodson J, et al.Simultaneous versus delayed hepatectomy for synchronous colorectal liver metastases: a systematic review and meta-analysis[J].HPB, 2018, 20(1): 11-19.DOI: 10.1016/j.hpb.2017.08.008.
[20]
Kazi M, Patkar S, Patel P, et al.Simultaneous resection of synchronous colorectal liver metastasis: Feasibility and development of a prediction model[J].Ann Hepatobiliary Pancreat Surg, 2023, 27(1): 40-48.DOI:10.14701/ahbps.22-043.
[21]
Frühling P, Strömberg C, Isaksson B, et al.A comparison of the simultaneous, liver-first, and colorectal-first strategies for surgical treatment of synchronous colorectal liver metastases at two major liver-surgery institutions in Sweden[J].HPB, 2023, 25(1): 26-36.DOI: 10.1016/j.hpb.2022.09.001.
[22]
Chen Q, Zhang R, Xing B, et al.Optimal surgical sequence for colorectal cancer liver metastases patients receiving colorectal cancer resection with simultaneous liver metastasis resection: a multicentre retrospective propensity score matching study[J].Int J Surg, 2022,106: 106952.DOI: 10.1016/j.ijsu.2022.106952.
[23]
Wang Y, Wen N, Xiong X, et al.Timing of surgery in patients with synchronous colorectal cancer liver metastases undergoing neoadjuvant chemotherapy: a propensity score analysis[J].World J Surg Oncol, 2023, 21(1): 276.DOI: 10.1186/s12957-023-03162-y.
[24]
Keck J, Gaedcke J, Ghadimi M, et al.Surgical therapy in patients with colorectal liver metastases[J].Digestion, 2022, 103(4): 245-252.DOI:10.1159/000524022.
[25]
Noda T, Takahashi H, Tei M, et al.Clinical outcomes of neoadjuvant chemotherapy for resectable colorectal liver metastasis with intermediate risk of postoperative recurrence: a multi-institutional retrospective study[J].Ann Gastroenterol Surg, 2022, 7(3): 479-490.DOI: 10.1002/ags3.12631.
[26]
Martin J, Petrillo A, Smyth EC, et al.Colorectal liver metastases:Current management and future perspectives[J].World J Clin Oncol,2020, 11(10): 761-808.DOI: 10.5306/wjco.v11.i10.761.
[27]
Lillemoe HA, Vauthey JN.Surgical approach to synchronous colorectal liver metastases: staged, combined, or reverse strategy[J].Hepatobiliary Surg Nutr, 2020, 9(1): 25-34.DOI: 10.21037/hbsn.2019.05.14.
[28]
中国医师协会外科医师分会, 中华医学会外科分会胃肠外科学组, 中华医学会外科分会结直肠外科学组, 等.中国结直肠癌肝转移诊断和综合治疗指南(2020版)[J].临床肝胆病杂志, 2021, 37(3):543-553.DOI:10.3969/j.issn.1001-5256.2021.03.009.Chinese College of Surgeons of Chinese Medical Doctor Association,Chinese Society Gastrointestinal Surgery of Chinese Society of Surgery of Chinese Medical Association, Chinese Society of Colorectal Surciety Chinese Society of Surgery of Chinese Medical Association,et al.China guideline for diagnosis and comprehensive treatment of colorectal liver metastases(2020 edition)[J].J Clin Hepatol, 2021,37(3): 543-553.DOI:10.3969/j.issn.1001-5256.2021.03.009.
[29]
张炜力, 周驰, 邓宇翔, 等.初始不可切除结直肠癌肝转移转化治疗结局影响因素分析[J].中华胃肠外科杂志, 2022, 25(1): 56-62.DOI:10.3760/cma.j.cn441530-20210718-00287.Zhang WL, Zhou C, Deng YX, et al.Analysis of influencing factors on the outcome of liver metastasis and transformation therapy for initially unresectable colorectal cancer[J].Chin J Gastrointest Surg, 2022,25(1): 56-62.DOI: 10.3760/cma.j.cn441530-20210718-00287.
[30]
张钰洋, 陈善稳, 王鹏远, 等.结直肠癌肝转移转化治疗的研究进展[J].中华胃肠外科杂志, 2021, 24(1): 85-93.DOI: 10.3760/cma.j.cn.441530-20200311-00135.Zhang YY, Chen SW, Wang PY, et al.Research progress of liver metastasis and transformation therapy for colorectal cancer[J].Chin J Gastrointest Surg, 2021, 24(1): 85-93.DOI: 10.3760/cma.j.cn.441530-20200311-00135.
[31]
张宜利, 李巍.结直肠癌肝转移转化治疗进展[J].腹部外科, 2021,34(4): 322-326.DOI:10.3969/j.issn.1003-5591.2021.04.016.Zhang YL, Li W.Recent advances in the treatment of colorectal liver metastasis[J].J Abdom Surg, 2021, 34(4): 322-326.DOI:10.3969/j.issn.1003-5591.2021.04.016.
[32]
王大强, 鞠后琼, 仲崇晗, 等.结直肠癌伴同时性不可切除肝转移转化治疗的疗效分析[J].中华普通外科杂志, 2023, 38(6): 407-411.DOI: 10.3760/cma.j.cn113855-20220817-00519.Wang DQ, Ju HQ, Zhong CH, et al.Conversion managment of colorectal cancer with simultaneous unresectable hepatic metastasis[J].Chin J Gen Surg, 2023, 38(6): 407-411.DOI: 10.3760/cma.j.cn113855-20220817-00519.
[33]
Sarkar J, Attwood K, Schwarz RE.Perioperative chemotherapy is associated with superior overall survival in patients with synchronous colorectal liver metastases[J].Ann Surg Oncol, 2023, 30(13): 7986-7995.DOI: 10.1245/s10434-023-14302-9.
[34]
Kawaguchi Y, Lillemoe HA, Vauthey JN.Dealing with an insufficient future liver remnant: portal vein embolization and two-stage hepatectomy[J].J Surg Oncol, 2019, 119(5): 594-603.DOI: 10.1002/jso.25430.
[35]
Imai K, Allard MA, Baba H, et al.Optimal patient selection for successful two-stage hepatectomy of bilateral colorectal liver metastases[J].Ann Gastroenterol Surg, 2021, 5(5): 634-638.DOI: 10.1002/ags3.12465.
[36]
Sandström P, Røsok BI, Sparrelid E, et al.ALPPS improves resectability compared with conventional two-stage hepatectomy in patients with advanced colorectal liver metastasis: results from a Scandinavian multicenter randomized controlled trial(LIGRO trial)[J].Ann Surg, 2018, 267(5): 833-840.DOI: 10.1097/SLA.0000000000002511.
[1] 王昭雨, 姜军. 乳腺癌外科治疗理论和技术的发展与挑战[J/OL]. 中华乳腺病杂志(电子版), 2025, 19(01): 1-5.
[2] 中华医学会骨科学分会关节外科学组. 下肢骨科手术术后肿胀防治专家共识(2024版)[J/OL]. 中华关节外科杂志(电子版), 2024, 18(06): 691-701.
[3] 谭飞, 王静, 曾健康, 李嘉欢, 李培杰, 汪昕, 乔永杰, 叶铄, 周胜虎. 顺行髓内钉与不同逆行技术治疗第5掌骨颈骨折[J/OL]. 中华关节外科杂志(电子版), 2024, 18(06): 742-750.
[4] 代永鸿, 杨匡洋, 吴征杰, 曾焰辉, 赵春鹏, 王军强, 吴新宝. 智能骨盆骨折微创复位机器人系统的早期疗效分析[J/OL]. 中华关节外科杂志(电子版), 2024, 18(06): 795-799.
[5] 王舒钰, 杨仕武, 陈君如, 巢凯, 马永钰, 刀娅, 洪伟, 高云鹏, 代如涛, 柏亚明, 曹辛, 吴骏. 胸腔镜手术治疗新生儿先天性膈疝疗效研究[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(06): 603-610.
[6] 黄晋杰, 李奕男, 王彩琴, 黄晓卉, 王荣昌. 结直肠癌肺转移术后复发性肺转移治疗进展[J/OL]. 中华普通外科学文献(电子版), 2025, 19(01): 50-54.
[7] 郝金锦, 王欢欢, 郑少祥, 陈文亮. 脂联素在结直肠癌中的作用[J/OL]. 中华普通外科学文献(电子版), 2025, 19(01): 61-65.
[8] 李国防, 陈凯, 管文贤, 刘颂. 消化道术后吻合口漏小鼠动物模型的建立[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(02): 162-165.
[9] 徐逸男. 不同术式治疗梗阻性左半结直肠癌的疗效观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 72-75.
[10] 孙莲, 马红萍, 吴文英. 局部进展期甲状腺癌患者外科处理[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 112-114.
[11] 张翀, 张宗明, 刘卓, 刘立民, 赵月, 齐晖. 肝门部胆管癌诊治进展[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 167-180.
[12] 陈宗杰, 胡添松. 肝外伤破裂患者治疗后胆漏发生影响因素分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 836-840.
[13] 沈成龙, 刘海晨, 周放, 郭健, 石志良, 侍新宇, 周国强, 何宋兵. 内脏脂肪面积及肌肉减少症对结直肠癌患者手术疗效及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2025, 14(01): 83-90.
[14] 袁佳莹, 范小彧, 费博, 喻春钊. 结直肠癌肝转移研究模型的现状及展望[J/OL]. 中华结直肠疾病电子杂志, 2025, 14(01): 40-46.
[15] 陈颖, 王一, 王璐, 孔德松, 章阳, 樊志敏. 结直肠癌类器官在中药及其有效成分研究中的应用进展[J/OL]. 中华结直肠疾病电子杂志, 2025, 14(01): 47-52.
阅读次数
全文


摘要